Abstract library

27 results for "Cingarlini".
#858 Metastatic Pancreatic Neuroendocrine Tumors with Ectopic Cushing Syndrome: Could Everolimus Be a Safe Therapeutic Option?
Introduction: Everolimus(E) has proved effective in prolonging PFS in advanced P-NETs. As E is a substrate of CYP3A4 co-administration with ketoconazole (k), a strong inhibitor of CYP3A4 used to control hypercortisolism, should be avoided.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Maria Vittoria Davì
#999 Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study
Introduction: Criteria other than RECIST are not validated for evaluation of response during treatment in pancreatic neuroendocrine tumors (pNETs). Preliminary evidence favors antiangiogenic properties of E.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini
Keywords: everolimus, pNET, P-CT
#1007 Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study
Introduction: Everolimus (E) acts on cancer progression, even inhibiting tumor angiogenesis. Both tumor vasculature and a normal one could undergo everolimus effect.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini
#1023 Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience
Introduction: STZ is the only FDA-approved antiblastic drug for well-/moderately-differentiated NETs. To date, no clear therapeutic sequence is defined for medical treatment of advanced pNETs.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Sara Cingarlini
#1024 Minimally Invasive Surgery for Pancreatic Neuroendocrine Tumors: Why Not?
Introduction: Recent evidence suggests that pancreatic neuroendocrine tumors (pNETs) are amenable to minimally invasive resections (MIPR).
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: doctor Anna Malpaga
#1165 Discrepancy Between Radiologic and Pathologic Measurements in Pancreatic Neuroendocrine Tumors: A Retrospective Study on 199 Patients
Introduction: Preoperative radiologic size of pancreatic neuroendocrine tumors (PNET) is a crucial parameter in selection of appropriate treatment especially for incidentally discovered lesions (<20 mm). The current guideline bases the therapeutic recommendations on the pathologic size.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: size NET
#1174 Long-Term Follow-Up of Resected Small (< 2 Cm) Asymptomatic Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors: Correlation Between Type of Resection, Histopathologic Features, and Outcome
Introduction: The surgical management of small, incidentally found sporadic non-functioning pancreatic neuroendocrine tumors (NF-PNET) is controversial
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: small
#1198 Role of Combined 68Ga-DOTATOC and 18F-FDG PET-CT in the Diagnostic Workup of Well Differentiated Pancreas Neuroendocrine Tumors (PanNETs): A Surgical Series
Introduction: PanNETs have a broad spectrum of aggressiveness. Somatostatin-receptor based functional imaging, [68Ga]DOTATOC-PET/CT (GP), is recommended in the diagnostic workup of PanNETs; preliminary evidences show that [18F]FDG-PET/CT (FP) can provide prognostic information.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1210 Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study.
Introduction: P-CT can evaluate inner perfusional features of primary and metastatic PanNETs; preliminary evidences suggest its potential role in predicting early response to anti-angiogenic therapies. Perfusional modifications induced by E in LM are not completely understood.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1226 Follow Up of ≤ 2 cm Non Functioning Pancreatic NETs in Patients with MEN1 Treated with Conservative Approach
Introduction: There is a current trend for conservative treatment of non functioning pancreatic NET (NF-PNETs), ≤ 2 cm, in patients with MEN1, which are reported to be associated with low risk of metastasis and death.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Maria Vittoria Davì
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.